 William Robinson
Concepts (850)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 93 | 2024 | 760 | 7.010 |
Why?
| | Skin Neoplasms | 49 | 2025 | 855 | 3.950 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 67 | 1.710 |
Why?
| | Mastocytosis | 3 | 2021 | 12 | 1.470 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2129 | 1.130 |
Why?
| | Spinal Fusion | 4 | 2022 | 251 | 0.930 |
Why?
| | Melanocytes | 7 | 2024 | 65 | 0.880 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2025 | 215 | 0.810 |
Why?
| | Mutation | 17 | 2022 | 3958 | 0.790 |
Why?
| | Vitiligo | 5 | 2024 | 42 | 0.760 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1430 | 0.760 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 60 | 0.750 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 77 | 0.750 |
Why?
| | Mucous Membrane | 2 | 2024 | 125 | 0.720 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2025 | 224 | 0.710 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.700 |
Why?
| | Piperazines | 7 | 2018 | 350 | 0.680 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 38 | 0.660 |
Why?
| | Middle Aged | 94 | 2024 | 33479 | 0.640 |
Why?
| | Spinal Fractures | 1 | 2020 | 73 | 0.630 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 172 | 0.610 |
Why?
| | Exome | 2 | 2017 | 231 | 0.610 |
Why?
| | Humans | 210 | 2025 | 137585 | 0.610 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 30 | 0.600 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 40 | 0.590 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 8 | 0.580 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.580 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 69 | 0.570 |
Why?
| | Humeral Head | 1 | 2017 | 14 | 0.570 |
Why?
| | Osteoporosis | 2 | 2020 | 243 | 0.560 |
Why?
| | Orthopedics | 1 | 2020 | 144 | 0.560 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 17 | 0.550 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 33 | 0.550 |
Why?
| | Skin Pigmentation | 4 | 2024 | 49 | 0.540 |
Why?
| | Intention | 1 | 2019 | 170 | 0.530 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 66 | 0.530 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 53 | 0.530 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2426 | 0.530 |
Why?
| | Female | 119 | 2025 | 73304 | 0.520 |
Why?
| | Databases, Factual | 4 | 2020 | 1357 | 0.520 |
Why?
| | Granulocytes | 26 | 1988 | 80 | 0.510 |
Why?
| | Hematopoiesis | 24 | 1988 | 192 | 0.510 |
Why?
| | Forecasting | 2 | 2017 | 389 | 0.500 |
Why?
| | MicroRNAs | 4 | 2023 | 692 | 0.500 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 16 | 0.480 |
Why?
| | Shoulder Joint | 1 | 2017 | 173 | 0.480 |
Why?
| | Osteoarthritis | 1 | 2017 | 185 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 115 | 0.470 |
Why?
| | Adult | 95 | 2025 | 37929 | 0.470 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1276 | 0.460 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 118 | 0.460 |
Why?
| | Male | 101 | 2025 | 67762 | 0.460 |
Why?
| | Phosphoproteins | 1 | 2017 | 338 | 0.450 |
Why?
| | Pyrimidines | 4 | 2008 | 470 | 0.450 |
Why?
| | Aged | 63 | 2024 | 23961 | 0.450 |
Why?
| | Aged, 80 and over | 21 | 2021 | 7635 | 0.430 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 36 | 0.430 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.420 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3412 | 0.420 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.410 |
Why?
| | Milk, Human | 1 | 2014 | 158 | 0.380 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 399 | 0.380 |
Why?
| | Military Personnel | 1 | 2019 | 544 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 36 | 0.370 |
Why?
| | Pyrroles | 3 | 2021 | 213 | 0.360 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 41 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1692 | 0.350 |
Why?
| | Triazines | 2 | 2021 | 43 | 0.350 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2253 | 0.350 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1396 | 0.340 |
Why?
| | Sulfonamides | 4 | 2020 | 513 | 0.340 |
Why?
| | Lymph Node Excision | 5 | 2021 | 171 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 77 | 0.330 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 45 | 0.330 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 352 | 0.330 |
Why?
| | Genes, p16 | 3 | 2007 | 20 | 0.320 |
Why?
| | Adenocarcinoma | 5 | 2016 | 940 | 0.320 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 246 | 0.310 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 82 | 0.300 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 539 | 0.300 |
Why?
| | Leukocytes | 14 | 1986 | 311 | 0.300 |
Why?
| | Lumbosacral Region | 2 | 2019 | 58 | 0.300 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1738 | 0.300 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 190 | 0.290 |
Why?
| | Treatment Outcome | 15 | 2022 | 10811 | 0.290 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 10 | 0.290 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 21 | 0.290 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 327 | 0.290 |
Why?
| | Cyclins | 1 | 2008 | 91 | 0.280 |
Why?
| | Quality Improvement | 2 | 2018 | 1178 | 0.280 |
Why?
| | Pyrazoles | 2 | 2021 | 423 | 0.280 |
Why?
| | Nitrophenols | 3 | 2017 | 34 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 648 | 0.280 |
Why?
| | Tretinoin | 4 | 2023 | 123 | 0.280 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 44 | 0.280 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 63 | 0.270 |
Why?
| | Tamoxifen | 3 | 2016 | 202 | 0.270 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 327 | 0.260 |
Why?
| | Prognosis | 14 | 2024 | 4030 | 0.260 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 44 | 0.260 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 93 | 0.250 |
Why?
| | Interferon-alpha | 6 | 2006 | 198 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 233 | 0.240 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 363 | 0.240 |
Why?
| | Hair Color | 2 | 2024 | 15 | 0.240 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 872 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 34 | 0.230 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 164 | 0.230 |
Why?
| | Liposarcoma | 1 | 2005 | 27 | 0.230 |
Why?
| | Epidermis | 2 | 2024 | 157 | 0.230 |
Why?
| | Follow-Up Studies | 12 | 2020 | 5131 | 0.230 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 385 | 0.230 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 29 | 0.220 |
Why?
| | Intestine, Small | 2 | 2024 | 156 | 0.220 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1062 | 0.220 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 396 | 0.220 |
Why?
| | Dasatinib | 1 | 2024 | 54 | 0.220 |
Why?
| | Hyperpigmentation | 1 | 2024 | 26 | 0.220 |
Why?
| | Lymph Nodes | 1 | 2006 | 491 | 0.210 |
Why?
| | Piperidines | 2 | 2018 | 206 | 0.210 |
Why?
| | Dacarbazine | 7 | 2012 | 98 | 0.210 |
Why?
| | Mice | 28 | 2024 | 17787 | 0.210 |
Why?
| | Burns | 7 | 1997 | 325 | 0.210 |
Why?
| | Hair Follicle | 3 | 2020 | 46 | 0.210 |
Why?
| | Genomics | 4 | 2024 | 795 | 0.210 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1389 | 0.210 |
Why?
| | Melatonin | 3 | 1994 | 150 | 0.210 |
Why?
| | Mice, Nude | 4 | 2020 | 698 | 0.210 |
Why?
| | Exons | 3 | 2019 | 355 | 0.210 |
Why?
| | Stem Cells | 4 | 2017 | 594 | 0.210 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 228 | 0.200 |
Why?
| | Flavonoids | 1 | 2003 | 85 | 0.200 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 17 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.200 |
Why?
| | Retrospective Studies | 17 | 2025 | 15657 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 801 | 0.200 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 156 | 0.200 |
Why?
| | Pedigree | 3 | 2024 | 514 | 0.190 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 137 | 0.190 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 411 | 0.190 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 258 | 0.190 |
Why?
| | Lordosis | 1 | 2022 | 16 | 0.190 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.190 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 406 | 0.190 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 8 | 0.190 |
Why?
| | Registries | 3 | 2020 | 2035 | 0.190 |
Why?
| | Clone Cells | 7 | 2010 | 265 | 0.180 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 42 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 1079 | 0.180 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 617 | 0.180 |
Why?
| | Risk Factors | 8 | 2020 | 10388 | 0.170 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1774 | 0.170 |
Why?
| | Interleukin-1 | 2 | 2019 | 965 | 0.170 |
Why?
| | Animals | 34 | 2024 | 36940 | 0.170 |
Why?
| | Sonication | 1 | 2020 | 13 | 0.170 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1066 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2001 | 54 | 0.170 |
Why?
| | Leukemia | 8 | 1988 | 240 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 900 | 0.170 |
Why?
| | Adult Stem Cells | 1 | 2020 | 40 | 0.170 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 33 | 0.160 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1457 | 0.160 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 78 | 0.160 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 3 | 0.160 |
Why?
| | Aniline Compounds | 1 | 2020 | 102 | 0.160 |
Why?
| | Finger Joint | 1 | 2019 | 8 | 0.160 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 955 | 0.160 |
Why?
| | Finger Phalanges | 1 | 2019 | 9 | 0.160 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.160 |
Why?
| | beta Catenin | 2 | 2020 | 253 | 0.150 |
Why?
| | Heart Neoplasms | 2 | 1999 | 50 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 54 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 95 | 0.150 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 452 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2019 | 33 | 0.150 |
Why?
| | Bone Density | 2 | 2020 | 489 | 0.150 |
Why?
| | RNA | 2 | 2016 | 921 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2020 | 143 | 0.150 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 45 | 0.150 |
Why?
| | Signal Transduction | 7 | 2023 | 5079 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | Reoperation | 2 | 2019 | 573 | 0.150 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 33 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 62 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Hospital Costs | 1 | 2018 | 117 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2022 | 3556 | 0.140 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 45 | 0.140 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 25 | 0.140 |
Why?
| | Adolescent | 35 | 2025 | 21513 | 0.140 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 316 | 0.140 |
Why?
| | Receptors, Androgen | 1 | 1998 | 150 | 0.140 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 91 | 0.140 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 79 | 0.140 |
Why?
| | Biofilms | 1 | 2020 | 260 | 0.140 |
Why?
| | Burns, Electric | 3 | 1986 | 26 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 196 | 0.130 |
Why?
| | Low Back Pain | 1 | 2019 | 108 | 0.130 |
Why?
| | Bone Marrow | 14 | 1983 | 286 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2018 | 233 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 237 | 0.130 |
Why?
| | Cisplatin | 4 | 2006 | 320 | 0.130 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 20 | 0.130 |
Why?
| | Adenine | 1 | 2018 | 271 | 0.130 |
Why?
| | Benzamides | 2 | 2008 | 216 | 0.130 |
Why?
| | Freezing | 4 | 2014 | 90 | 0.130 |
Why?
| | Membrane Proteins | 4 | 2020 | 1164 | 0.130 |
Why?
| | Preservation, Biological | 3 | 2014 | 8 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 521 | 0.130 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 86 | 0.130 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 286 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 257 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 122 | 0.120 |
Why?
| | Drug Synergism | 4 | 2018 | 382 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 404 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2000 | 771 | 0.120 |
Why?
| | Apoptosis | 4 | 2018 | 2553 | 0.120 |
Why?
| | Interferon Type I | 4 | 1994 | 140 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2526 | 0.120 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1238 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 100 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1266 | 0.120 |
Why?
| | Cell Cycle | 3 | 2010 | 601 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 976 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 319 | 0.120 |
Why?
| | Radiography | 1 | 2017 | 822 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 80 | 0.120 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 27 | 0.120 |
Why?
| | Leukocyte Count | 20 | 1988 | 329 | 0.120 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 271 | 0.110 |
Why?
| | Desiccation | 1 | 2014 | 19 | 0.110 |
Why?
| | Lymphoma | 4 | 1991 | 208 | 0.110 |
Why?
| | Survival Analysis | 6 | 2010 | 1325 | 0.110 |
Why?
| | Cell Division | 11 | 1998 | 794 | 0.110 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 606 | 0.110 |
Why?
| | Cell Survival | 8 | 2018 | 1120 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 706 | 0.110 |
Why?
| | Survival Rate | 8 | 2024 | 1972 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.110 |
Why?
| | Peptides | 2 | 2008 | 985 | 0.110 |
Why?
| | Child | 17 | 2025 | 21935 | 0.110 |
Why?
| | Perineum | 1 | 1993 | 32 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 436 | 0.110 |
Why?
| | Basigin | 1 | 2013 | 25 | 0.100 |
Why?
| | Internet | 1 | 2018 | 655 | 0.100 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 27 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2057 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 119 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.100 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 6 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 55 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2475 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 59 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 317 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 76 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 165 | 0.100 |
Why?
| | Alleles | 2 | 2022 | 891 | 0.100 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 19 | 0.100 |
Why?
| | Vitamins | 1 | 1994 | 185 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 900 | 0.100 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.090 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 111 | 0.090 |
Why?
| | Pyrimidinones | 2 | 2025 | 113 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 812 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 683 | 0.090 |
Why?
| | Peer Review | 1 | 2012 | 49 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2828 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 55 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 399 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 46 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 37 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3196 | 0.090 |
Why?
| | United States | 3 | 2020 | 14841 | 0.090 |
Why?
| | History, 21st Century | 1 | 2012 | 213 | 0.090 |
Why?
| | Keratinocytes | 2 | 2024 | 249 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1991 | 363 | 0.090 |
Why?
| | Agranulocytosis | 6 | 1986 | 30 | 0.090 |
Why?
| | History, 20th Century | 1 | 2012 | 325 | 0.080 |
Why?
| | Pancreatitis | 1 | 1991 | 134 | 0.080 |
Why?
| | Blast Crisis | 1 | 1990 | 33 | 0.080 |
Why?
| | Cyclosporine | 1 | 1991 | 268 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 2031 | 0.080 |
Why?
| | Time Factors | 15 | 2019 | 6828 | 0.080 |
Why?
| | Neoplasms | 5 | 2018 | 2671 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 252 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 342 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 250 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 124 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 686 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 14 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4193 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1353 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2691 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 778 | 0.080 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 480 | 0.080 |
Why?
| | Cell Differentiation | 7 | 2015 | 1991 | 0.080 |
Why?
| | Osteonecrosis | 2 | 1986 | 24 | 0.080 |
Why?
| | Neutrophils | 8 | 1988 | 1238 | 0.080 |
Why?
| | Lithium | 5 | 1986 | 43 | 0.070 |
Why?
| | Cyclin D | 1 | 2008 | 9 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2013 | 614 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 130 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2837 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 314 | 0.070 |
Why?
| | Lymphocytes | 7 | 2006 | 397 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2181 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 77 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1719 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 843 | 0.070 |
Why?
| | Risk | 2 | 2019 | 912 | 0.070 |
Why?
| | Skull | 2 | 1986 | 139 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 44 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 183 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 644 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 804 | 0.070 |
Why?
| | Australia | 2 | 2023 | 315 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 14 | 0.070 |
Why?
| | Cell Movement | 5 | 2015 | 967 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 145 | 0.070 |
Why?
| | Oligosaccharides | 1 | 2007 | 60 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 226 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.070 |
Why?
| | Factor VIII | 1 | 1987 | 98 | 0.070 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.070 |
Why?
| | Cell Self Renewal | 2 | 2017 | 56 | 0.070 |
Why?
| | Vaccinia virus | 2 | 1998 | 43 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2008 | 523 | 0.060 |
Why?
| | Health Education | 1 | 1990 | 341 | 0.060 |
Why?
| | Disease Progression | 2 | 2013 | 2757 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 135 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 528 | 0.060 |
Why?
| | Education, Medical | 1 | 1990 | 266 | 0.060 |
Why?
| | Quinazolines | 1 | 2008 | 251 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 13209 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 404 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1783 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1303 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 40 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 120 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3566 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 19 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 23 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 12 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 20 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 85 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 98 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 139 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 167 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 425 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 66 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 7 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 558 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 1 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1502 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 25 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 63 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 15 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1092 | 0.060 |
Why?
| | Infant | 2 | 2019 | 9465 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 110 | 0.060 |
Why?
| | Forearm | 1 | 1985 | 119 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 510 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 104 | 0.060 |
Why?
| | Wrist | 1 | 1985 | 54 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 708 | 0.060 |
Why?
| | Hand Injuries | 1 | 1985 | 31 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 47 | 0.060 |
Why?
| | Burns, Chemical | 1 | 1985 | 32 | 0.060 |
Why?
| | Skin Transplantation | 1 | 1985 | 85 | 0.060 |
Why?
| | Acute Disease | 6 | 1991 | 1007 | 0.060 |
Why?
| | Macrophages | 4 | 1988 | 1547 | 0.060 |
Why?
| | Protein Transport | 2 | 2018 | 445 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 112 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 219 | 0.060 |
Why?
| | Blood Cell Count | 5 | 1995 | 55 | 0.060 |
Why?
| | Monocytes | 5 | 1983 | 563 | 0.060 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 10 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 327 | 0.050 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 658 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2189 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1759 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 90 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 52 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 168 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 460 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 815 | 0.050 |
Why?
| | Urine | 4 | 1973 | 59 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 392 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 90 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2900 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 28 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 35 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 108 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 71 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 146 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 455 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 916 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 268 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 99 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 3 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 58 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 350 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1627 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 47 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 192 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 23 | 0.050 |
Why?
| | Neck Pain | 1 | 2021 | 26 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 50 | 0.050 |
Why?
| | Leukocytosis | 4 | 1974 | 30 | 0.050 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1050 | 0.050 |
Why?
| | Antigens | 2 | 1983 | 357 | 0.050 |
Why?
| | Gene Expression | 3 | 2008 | 1502 | 0.050 |
Why?
| | Isotretinoin | 2 | 1994 | 26 | 0.050 |
Why?
| | Incidence | 3 | 2009 | 2804 | 0.040 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 17 | 0.040 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 46 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4295 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 1983 | 247 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 23 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 342 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 132 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 816 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 16 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 545 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 9 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 5 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 332 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 104 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 50 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 630 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 13 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 92 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 26 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 2892 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 140 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 60 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3295 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 220 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 34 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 17 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 840 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 160 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2833 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 21 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 116 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 43 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1081 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 89 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 23 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 247 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 157 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 147 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 43 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 37 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 95 | 0.040 |
Why?
| | Arthritis | 1 | 2019 | 95 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2019 | 123 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 96 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 138 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1994 | 115 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 500 | 0.040 |
Why?
| | Levamisole | 1 | 1977 | 19 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 188 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 38 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 88 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 377 | 0.030 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 80 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 375 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 141 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 84 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 169 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 118 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 393 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 72 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 19 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 180 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 50 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 42 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 61 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 124 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 320 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 64 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 200 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 80 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 15 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 138 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 71 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1236 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 189 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 172 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 1043 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 455 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 786 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 161 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 16 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 22 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 391 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 182 | 0.030 |
Why?
| | Veins | 1 | 1995 | 63 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 68 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 12 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 413 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 10 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2224 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 34 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 297 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 297 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 353 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 81 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 500 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 97 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 15 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 21 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 30 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 50 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 18 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 13 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 128 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 44 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 112 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 367 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 33 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 90 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 105 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1994 | 316 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1710 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 77 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 194 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 183 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 39 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 38 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 98 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 60 | 0.020 |
Why?
| | Phenytoin | 2 | 1962 | 21 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 36 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 156 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1994 | 177 | 0.020 |
Why?
| | Iron | 3 | 1989 | 313 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 43 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1096 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 674 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1178 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 149 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 91 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 897 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 257 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 406 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 87 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 429 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 34 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 304 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 367 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 195 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 192 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 240 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 217 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 35 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 268 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 24 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 230 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 858 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 366 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 231 | 0.020 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5757 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 601 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 127 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 14 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 52 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 34 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 251 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 150 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1226 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 515 | 0.020 |
Why?
| | California | 1 | 1991 | 431 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 622 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 420 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 468 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 34 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 238 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 24 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 175 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1483 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 12 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 118 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 26 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 87 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 767 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 189 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 125 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 170 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4565 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 679 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 99 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 530 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 13 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 148 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 136 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 259 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 20 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 111 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 31 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 157 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 335 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 19 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 109 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 48 | 0.020 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 35 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
| | MART-1 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 66 | 0.020 |
Why?
| | Hemoglobins | 1 | 1988 | 353 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 852 | 0.020 |
Why?
| | Metaproterenol | 1 | 1985 | 2 | 0.020 |
Why?
| | Culture Media | 4 | 1977 | 165 | 0.020 |
Why?
| | Prospective Studies | 4 | 2005 | 7604 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 2006 | 786 | 0.020 |
Why?
| | Reference Standards | 1 | 2006 | 186 | 0.020 |
Why?
| | Double-Blind Method | 3 | 1998 | 1993 | 0.010 |
Why?
| | Extremities | 1 | 2006 | 131 | 0.010 |
Why?
| | Fatigue | 1 | 2007 | 329 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 23 | 0.010 |
Why?
| | Platelet Count | 2 | 1986 | 86 | 0.010 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 434 | 0.010 |
Why?
| | Lower Extremity | 1 | 2009 | 427 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 521 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 889 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 50 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 13 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 700 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 395 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 483 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 139 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 514 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 27 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 408 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 358 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 245 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 164 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 493 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 288 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 389 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 151 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 246 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 762 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 114 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 9 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 187 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 158 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1943 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 339 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 43 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 17 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 8 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 71 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 16 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 47 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 63 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 620 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 41 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 55 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 248 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 759 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 274 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 409 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 445 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 172 | 0.010 |
Why?
| | Pain | 1 | 2007 | 756 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 47 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 238 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1020 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3284 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 6 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 220 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1129 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 15 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 352 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 146 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 57 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 325 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 197 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 62 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 150 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 6763 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 1 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 80 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 24 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 55 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 166 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 77 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 363 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 40 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 617 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 390 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1496 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 60 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 96 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 61 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 27 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 3 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 168 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 945 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 585 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 76 | 0.010 |
Why?
| | Agar | 1 | 1977 | 12 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 560 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 398 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 665 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 639 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 55 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1167 | 0.010 |
Why?
| | Groin | 1 | 1995 | 9 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 169 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 380 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 7 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 4 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 581 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 2 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 10 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 20 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 182 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 30 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 62 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 132 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 11074 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 25 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 52 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 106 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 89 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 212 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1996 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 9 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 322 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 169 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 2295 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 252 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 87 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 362 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 343 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2607 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1215 | 0.010 |
Why?
| | Arm | 2 | 1985 | 104 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 1 | 0.000 |
Why?
| | Perfusion | 1 | 1970 | 213 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 81 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 199 | 0.000 |
Why?
| | Ferritins | 1 | 1989 | 64 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 92 | 0.000 |
Why?
| | Skin | 1 | 1994 | 752 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 298 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 5 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 758 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 35 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 37 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 47 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 31 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 15 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 70 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 53 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 207 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 90 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 176 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 3 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 12 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 26 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 5 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 53 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2654 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 52 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5647 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2847 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 269 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 474 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 182 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 293 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 11 | 0.000 |
Why?
| | Fever | 1 | 1984 | 306 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 822 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 224 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 409 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 57 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 318 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 367 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 11 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 40 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 327 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1786 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 629 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 179 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 19 | 0.000 |
Why?
| | Blood | 1 | 1977 | 107 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 95 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 324 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 570 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1459 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 10 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1060 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 58 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 78 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1793 | 0.000 |
Why?
| | Leg | 1 | 1972 | 236 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 62 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 143 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 411 | 0.000 |
Why?
| | Swine | 1 | 1970 | 775 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 856 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|